In a long-term study, researchers found that once people stop taking GLP-1s and other weight-loss drugs, they tend to rapidly regain the pounds they lost
For many patients, GLP-1s have delivered the most effective weight-loss results of their lives. But one uncomfortable question looms, like a jolt from a good dream no one wants to wake up from: what happens when you stop?
That question is now starting to get answers.
According to a new systematic review and meta-analysis from researchers at the University of Oxford, weight regain often begins quickly once GLP-1 treatment ends — and faster than it does after ending traditional diet and exercise programs.
The study, published this week in The BMJ, lands amid evidence showing that roughly half of patients discontinue GLP-1 treatment within 12 months and as the National Institute for Health and Care Excellence recommends post-treatment support for at least a year.
To better understand what happens after patients stop taking weight-loss drugs, researchers reviewed 37 studies involving 9,341 adults who discontinued medications ranging from older options like orlistat to newer GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Zepbound).
Participants had been on treatment for an average of 39 weeks and were tracked for roughly 32 weeks after stopping.
Across the data, weight increased by an average of about 0.9 pounds per month after medication ended. At that pace, researchers estimate patients would return to their starting weight within roughly 18 months to two years. For newer GLP-1 medications, weight regain was even faster, averaging about 1.8 pounds per month.
A similar pattern emerged across cardiometabolic markers, including HbA1c, fasting glucose, blood pressure, cholesterol and triglycerides, which improved during treatment but are projected to return to baseline levels within roughly 1.4 years after medication ended.
By comparison, patients regained weight faster after stopping weight-loss drugs than after ending diet and exercise programs (about 0.7 pounds per month), independent of initial weight loss. Behavioral support led to greater weight loss during treatment but did little to slow regain once medication ended, researchers found.
The findings held up across three different analytical approaches, researchers said, while noting limited data on newer GLP-1 drugs and relatively short post-treatment follow-up periods that required some modeled projections.
What the Findings Mean for the Future of Obesity
Lead author Dr. Sam West, a postdoctoral researcher at the Nuffield Department of Primary Care Health Sciences at the University of Oxford, said in a release that the findings highlight both the promise and the limitations of weight-loss medications, which are transforming obesity treatment but are not a standalone solution.
“Our analysis shows that people tend to regain weight rapidly after stopping — faster than we see with behavioral programs,” Dr. West said. “This isn’t a failing of the medicines — it reflects the nature of obesity as a chronic, relapsing condition. It sounds a cautionary note for short-term use without a more comprehensive approach to weight management.”
That faster regain could reflect the fact that patients using medication don’t need to consciously practice dietary changes to lose weight, senior author and associate professor Dimitrios Koutoukidis said — meaning they may not develop the practical strategies needed to keep the weight off once treatment stops.
The real-world implications may be especially pronounced in the U.K., where an estimated nine in 10 people currently using weight-loss medications are purchasing them privately, often without the clinical oversight and behavioral support that is needed.
It’s a dynamic likely playing out in the U.S. as well, where access to GLP-1s has expanded rapidly beyond traditional healthcare settings. And while medication may seem like a straightforward solution, obesity itself is anything but simple, joint senior author and professor Susan Jebb points out.
“Obesity is a chronic, relapsing condition, not a short-term problem with a quick fix,” she said. “When people lose weight through changes to their diet and activity, they’re practicing the skills that help maintain that loss.”
Strength Training, Proper Nutrition Guidance Come Into Focus
The relative ease of medication, she suggested, may allow weight to come off without building the skills required to sustain it long term.
“These findings underscore the need for a more holistic and long-term approach to weight management, and increased emphasis on the importance of primary prevention of weight gain,” Jebb said. “For practitioners prescribing, patients receiving and people choosing to purchase these medications privately, it’s important to understand the risks of rapid weight regain if treatment ceases – and the value of wraparound behavioural support.”
While many fitness and wellness industry leaders have emphasized the importance of strength training and comprehensive nutrition support for long-term weight management, another avenue may be emerging: microdosing. By definition, microdosing involves smaller, more flexible doses, which some see as a better fit for cautious patients or those navigating side effects.
Although microdosing has gained interest among longevity-focused clinicians for its potential benefits, it also plays a role for patients who have already reached their goal weight on a GLP-1, according to telehealth platform Midi Health.
Behavioral health platform Noom recently entered the microdosing conversation with the launch of Proactive Health Microdose GLP-1 Rx, a preventive health program that pairs low-dose GLP-1 medication with biomarker testing and behavioral coaching.
Another company that moved into the microdose space is FuturHealth, offering low-dose compounded semaglutide and tirzepatide alongside what the weight management company describes as a comprehensive support model.
